A roll-over Study in Patients With Endogenous Cushing's Syndrome

An open-label, multi-center, roll-over study to assess long term safety in patients with endogenous Cushing's syndrome who have completed a prior Novartis-sponsored osilodrostat (LCI699) study and are judged by the investigator to benefit from continued treatment with osilodrostat

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222646

Enrollment

137

Registered

2014-11-06

Start date

2014-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

investigational material(s) Generic name etc : INN of investigational material : Osilodrostat phosphate Therapeutic category code : 249 Other hormone preparations (including antihormone preparations)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
safety efficacy -	—

Secondary

Measure	Time frame
efficacy	—

Countries

Europe, Japan, North America

Outcome results